September 20 - 23, 2014
Sheraton Philadelphia Downtown
Philadelphia, Pennsylvania, USA
Abstract submission deadline: Friday, August 8
Advance registration deadline: Monday, August 4
Continental Breakfast7:00 a.m.-8:00 a.m. Plenary Session 5: Stem CellsSession Chairperson: Emmanuelle Passegué, UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, Calif.8:00 a.m.-10:00 a.m.
Regulation of self-renewal in cancer stem cellsPier Giuseppe Pelicci, European Institute of Oncology, Milan, Italy
Decoding leukemia stem cell RNA recodingCatriona Jamieson, UCSD Moores Cancer Center, San Diego, Calif.
Competitive strategies of transformed HSCs: Lessons learned from CML biologyEmmanuelle Passegué
SRSF2 mutations impair hematopoietic differentiation by altering exonic splicing enhancer preference Omar Abdel-Wahab, Memorial Sloan Kettering Cancer Center, New York, N.Y.
Break10:00 a.m.-10:15 a.m.
Concurrent Sessions 3-410:15 a.m.-12:15 p.m. Concurrent Session 3: LymphomaSession Chairperson: Louis M. Staudt, National Cancer Institute, Bethesda, Md. Therapies of lymphoma targeting oncogenic signaling pathwaysLouis M. Staudt
Identification of targetable vulnerabilities in lymphomaMargaret A. Shipp, Dana-Farber Cancer Institute, Boston, Mass.
The genetic basis of diffuse large B-cell lymphomaLaura Pasqualucci, Columbia University Irving Comprehensive Cancer Center, New York, N.Y.
Patient-derived tumorgrafts from primary peripheral T-Cell lymphoma represent innovative models to design patients’ tailored therapiesGiorgio Inghirami, Weill Cornell Medical College, New York, N.Y.
DLBCL tumors are sensitized to ferroptosis, a regulated form of nonapoptotic cell deathWan Seok Yang, Columbia University, New York, N.Y.*
Concurrent Session 4: Myelodysplastic Syndrome and Myeloproliferative NeoplasmsSession Chairperson: Ross L. Levine, Memorial Sloan Kettering Cancer Center, New York, N.Y. Role of JAK-STAT pathway activation in MPN pathogenesis and therapeutic responseRoss L. Levine
Interpreting the role of acquired gene mutations in defining clinical outcome and treatment responseElli Papaemmanuil, Sanger Institute, Hinxton, U.K.
Molecular profiling of MDS for precision therapySeishi Ogawa, Kyoto University, Kyoto, Japan
Pathogenesis and clonal evolution of myeloproliferative neoplasmsRadek C. Skoda, University Hospital Basel, Basel, Switzerland
Mutant U2AF1 alters hematopoiesis and pre-mRNA splicing in transgenic miceCara Lunn Shirai, Washington University in St. Louis, St. Louis, Mo.*
Lunch12:15 p.m.-12:45 p.m.
Plenary Session 6: EpigeneticsSession Chairperson: Scott A. Armstrong, Memorial Sloan Kettering Cancer Center, New York, N.Y.12:45 p.m.-3:00 p.m.
Targeting epigenetic mechanisms in leukemiaScott A. Armstrong
DNA methylation, the cancer epigenome, and translational implicationsStephen B. Baylin, Johns Hopkins University School of Medicine, Baltimore, Md.
Epigenetic programming and therapy in germinal center derived B-cell lymphomasAri M. Melnick, Weill Cornell Medical College, New York, N.Y.
Chemical modulation of chromatin structure and functionJames E. Bradner, Dana-Farber Cancer Institute, Boston, Mass.
*Short talks from proffered abstracts